Here's why the Recce (ASX:RCE) share price is rocketing 12% today

The company's latest clinial trial update seems to have excited investors…

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is soaring today. This comes after the pharmaceutical company provided an update on its clinical trial for the treatment of burn wound infections.

At the time of writing, the Recce share price is up 12.21% to 96.5 cents. In comparison, the All Ordinaries (ASX: XAO) is up 0.51% to 7,567.7 points.

What did Recce announce?

The Recce share price is surging after the company reported positive results for its broad-spectrum antibiotic Recce 327 drug.

The phase I/II study assessed the safety and efficacy of Recce 327 against infectious bacteria on burn wounds in patients.

As such, investigators reviewed the findings and noted a visible infection reduction within the first 24 hours of treatment. Patients with acute infected wounds completely recovered, requiring no further treatment. Investigators adopted a shorter five-day treatment protocol for these patients.

Those who had more severe surface area wounds were given a seven-day timeframe, resulting in a similar outcome.

Initially, the trial had been scheduled to run over the 14 days. Two cohorts of patients would either receive Recce 327 daily or three times per week.

Recce advised that the study is ongoing, with further patient enrolment expected by early 2022.

Once the trial is completed, clinicians will review the results and decide upon the best standards of care for future programs. In addition, burn wound specialists will oversee the delivery of Recce 327 via a spray-on formulation.

The trial is being sponsored by the Western Australian government's Department of Health. It is taking place at the Fiona Stanley Hospital (Burns Unit) in Perth.

Commenting on the results fuelling the Recce share price today, CEO James Graham said:

We are pleased with the progress of our lead compound, R327, in patients harbouring serious burn wound infections. This initial update builds upon strong pre-clinical data demonstrating fast and efficient killing activity against common and problematic bacterial strains, and we are excited for the potential of R327 in the clinic. We look forward to updating shareholders of further human clinical data points as this trial progresses.

Recce share price summary

Despite today's euphoric rise, the Recce share price has had a disappointing 12 months, falling by around 20%. When looking at year-to-date, it is hovering around 9% lower.

Based on today's price, Recce presides a market capitalisation of roughly $149.45 million, with approximately 173.79 million shares on issue.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »